# Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

> **NCT05241340** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Methodist Hospital Research Institute** · enrollment: 33 (estimated)

## Conditions studied

- Urothelial Carcinoma Bladder

## Interventions

- **DRUG:** Sasanlimab
- **RADIATION:** Stereotactic Body Radiation Therapy
- **PROCEDURE:** Radical Cystectomy + pelvic lymph node dissection + urinary diversion

## Key facts

- **NCT ID:** NCT05241340
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-15
- **Primary completion:** 2025-08-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05241340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05241340, "Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05241340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*